Search

Additional file 2: Table S2. All PCR primers used in this research.

Additional file 1: Table S1. All siRNAs/shRNAs used in this research.

Additional file 2: Table S2. The abbreviations, sample numbers and full names of various tumors in TCGA database.

Additional file 1: Table S1. The alterations frequency of m6A regulators across 15 cancer types.

Zheng Y, Gao Y, Li X, et al. Onco Targets Ther.2018;11:4965–4977. On page 4972, the authors found an error in which theimages for Figure 4A PC3 Blank and Figure 4B 22RV1Blank were mistakenly duplicated. Upon realising theerror, the authors repeated the knockdown experimentdescribed in Figure 4 and were able to show resultsconsistent with those described in the original article.The authors provided a description of the experimentprocedure used for the relative colony counts and theraw data from both the original and repeated experimentsused to generate the results shown in Figure 4Aand Figure 4B. See revised Figure 4 below.The authors and the editor have confirmed that the correctionof the images has no significant impact on the conclusionsof the study.Read the original article

Objective. MicroRNA-124 (miR-124) was revealed to be an attractive prognostic tumour biomarker in recent studies. However, the results remain inconclusive. Hence, this meta-analysis was carried out to clarify the precise predictive value of miR-124. Materials and Methods. Relevant studies were searched in PubMed, EMBASE, Web of Science, and the Cochrane Library up to October 2018. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were extracted from the selected studies. Results. A total of 29 articles investigating the correlation between miR-124 expression and prognosis were initially identified. The pooled HR for overall survival (OS) of high miR-124 expression in multiple cancers was 0.55 (95%CI=0.50–0.61). Disease-free survival (DFS)/progression-free survival (HR=0.48, 95%CI=0.38–0.61) revealed a protective role of increased miR-124 expression. Epigenetic hypermethylation of miR-124 mediated the silencing of its expression, which is correlated significantly with unfavourable survival (OS: HR=2.06, 95%CI=1.68–2.53; DFS/recurrence-free survival: HR=2.77, 95%CI=1.85–4.16). Conclusions. Taken together, our results suggest that miR-124 plays an antioncogenic role in various tumors, such as lung cancer and colorectal cancer. If methylation of miR-124 could be prevented, progression and metastasis would be improved; thus, miR-124 may be a promising biomarker and novel therapeutic target. Further large-scale studies are needed to confirm this possible effect.

Flexible driving is essential in enhancing security during human-robot interactions and improving the adaptability of robots to complex environments. Based on these principles, we developed a variable stiffness actuator with automatic rigidity/ compliance switching. The actuator contains two motors-one for position control and the other for adjusting the stiffness. The stiffness adjustment motor independently alters stiffness through regulating the distance between the output shaft and the spring sliders. The function of automatic rigidity/compliance switching is realized through turning four electromagnets on or off to make sucker up or down. We set up an experimental platform to verify the automatic switching function for rigid and compliant characteristics. Results showed that the actuator can cover a wide range of stiffness and provide reliable rigidity/compliance switching.

A variable stiffness actuator is proposed according to the human ergonomic joint actuation mechanism and applied to an elbow rehabilitation robot. The robot employs an antagonistic compliant driving actuation to ensure rehabilitation training effectiveness and the patient's safety even under the condition of spasm. The robot joint stiffness and position can be controlled simultaneously by using the Feldman equilibrium position control theory, experimental verification is made to verify the nonlinear spring elements in the driving mechanism.